Sydney Menack

律師

Sydney Menack focuses her practice primarily on US Food and Drug Administration (FDA) regulatory and compliance matters relating to the approval, promotion, development, manufacturing, and sale of drugs and biologics, medical devices, cosmetics, dietary supplements, and food products. Sydney also counsels hospitals and other healthcare providers and entities on a variety of complex compliance matters and enforcement actions involving the False Claims Act (FCA), the Anti-Kickback Statute (AKS), the Stark Law, state licensure requirements, the corporate practice of medicine, and digital health and privacy laws.

Sydney has experience advising and representing a range of healthcare providers including physicians, dental practices, optometrists and ophthalmologists, hospice facilities, home health agencies, long-term assisted living and skilled nursing facilities, and independent clinical laboratories on regulatory and transactional matters and in government investigations involving FCA allegations. Sydney’s practice also includes counseling providers and companies in the life science sector, including medical device manufacturers, DME suppliers, pharmaceutical companies, and cosmetics companies, on FDA and Drug Enforcement Administration (DEA) compliance and enforcement matters.

Sydney earned her J.D. from University of Maryland Francis King Carey School of Law, during which time she served as the editor-in-chief for the Journal of Health Care Law and Policy.

University of Maryland School of Law, 2022, J.D., cum laude
University of Miami, 2019, B.A., psychology, magna cum laude

District of Columbia
Maryland

Member, DC Women’s Bar Association

Member, Food and Drug Law Institute

Member, American Health Law Association

Recipient, William P. Cunningham Award

Health Law Certificate, University of Maryland School of Law